Human Thyroid Cancer: Membrane Thyrotropin Binding and Adenylate Cyclase Activity

Carayon, Pierre; Thomas-Morvan, Colette; Castanas, Elias; Tubiana, M

doi:10.1210/jcem-51-4-915

Cited by 91 publications

(59 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TSH increases adenylate cyclase activity and cAMP levels in vitro, thereby leading to thyroid cell growth (22). The clinical value of TSH suppression has been documented by a retrospective study by Pujol et al (7).…”

Section: Discussionmentioning

confidence: 99%

Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma

et al. 1999

View full text Add to dashboard Cite

Objective: Although in most cases differentiated thyroid carcinoma (DTC) responds to surgery and radioiodine (RaI) therapy, some patients will have recurrence and eventually cancer-related death. However, although various prognostic factors of DTC have been identified (e.g. staging, suppressed thyrotropin), none of the previous studies have assessed simultaneously their role in multivariate analysis. Design and Methods:In this retrospective population-based study, we reviewed the clinicopathological data of 254 DTC patients treated in eastern Finland during the years 1976-1995, for clinical characteristics, primary treatment, follow-up and cancer recurrence. Tumor stage was based on pathological tumor-node-metastasis (pTNM) classification, and histopathological specimens were reevaluated. Results: DTC recurrence occurred in 33 patients (13%). In univariate analyses, the predictors of recurrence were older age (>60 years, P < 0.05), follicular tumor type (P < 0.01), pTNM classification system (P < 0.05) and post-ablative radioiodine uptake outside the neck (P < 0.05). Non-suppressed serum thyrotropin (TSH) and elevated serum thyroglobulin (>3 mg/l) measured one year after operation were both related to tumor recurrence (P < 0.05 and P < 0.001 respectively). In multivariate analysis the independent predictors for recurrence were both elevated thyroglobulin (P < 0.001) and non-suppressed TSH (P < 0.05) independent of histology, pTNM stage and RaI uptake. Adjusted risk ratio for recurrence of DTC for unsuppressed thyrotropin was 2.3, for elevated thyroglobulin 14.0 and, if both conditions were present, the risk ratio increased to 45.1. Conclusion: Our results suggest that both non-suppressed serum TSH and elevated serum thyroglobulin are related to an increased risk of DTC recurrence independent of tumor type and pTNM stage.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Benign and malignant thyroid tumours express functional TSH receptors on the plasma membrane (Ichikawa et al 1976) and TSH increases adenylate cyclase activity leading to cAMP production and cell growth through stimulation of these receptors in vitro (Carayon et al 1980). Importantly, the expression of TSH receptors in DTC has been associated with an improved prognosis (Shi et al 1993).…”

Section: :11mentioning

confidence: 99%

WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?

Nieto¹,

Boelaert²

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Differentiated thyroid cancer is the most common endocrine malignancy and the incidence is increasing rapidly worldwide. Appropriate diagnosis and post-treatment monitoring of patients with thyroid tumours are critical. Fine needle aspiration cytology remains the gold standard for diagnosing thyroid cancer, and although there have been significant refinements to this technique, diagnostic surgery is often required for patients suspected to have malignancy. Serum thyroid-stimulating hormone (TSH) is higher in patients with malignant thyroid nodules than in those with benign disease, and TSH is proportionally increased in more aggressive tumours. Importantly, we have shown that the pre-operative serum TSH concentration independently predicts the presence of malignancy in subjects presenting with thyroid nodules. Establishing the use of TSH measurements in algorithms identifying high-risk thyroid nodules in routine clinical practice represents an exciting, cost-efficient and non-invasive approach to optimise thyroid cancer diagnosis. Binding of TSH to receptors on thyrocytes stimulates a number of growth promoting pathways both in normal and malignant thyroid cells, and TSH suppression with high doses of levothyroxine is routinely used after thyroidectomy to prevent cancer recurrence, especially in high-risk tumours. This review examines the relationship between serum TSH and thyroid cancer and reflects on the clinical potential of TSH measurements in diagnosis and disease monitoring.

show abstract

“…This benefit may be limited by changes in TSH receptors that occur in thyroid cancer cells (18)(19)(20)(21). Such decreased TSH responsiveness could render some thyroid cancer cells less susceptible to manipulation of TSH concentrations.…”

Section: Introductionmentioning

confidence: 99%

Endogenous Thyrotropin and Triiodothyronine Concentrations in Individuals with Thyroid Cancer

Jonklaas

Nsouli-Maktabi

Soldin

2008

Thyroid

113

102

View full text Add to dashboard Cite

Background: Thyroid hormone suppression therapy is associated with decreased recurrence rates and improved survival in patients with differentiated thyroid cancer. Recently higher baseline thyrotropin (TSH) levels have been found to be associated with a postoperative diagnosis of differentiated thyroid cancer. Our objective was to confirm whether preoperative TSH levels were higher in patients who were diagnosed with differentiated thyroid cancer after undergoing thyroidectomy, compared with patients who were found to have benign disease. We also sought to determine whether thyroid hormone levels were lower in the patients with malignancy. Methods: The study was a retrospective analysis of a prospective study. The study setting was the General Clinical Research Center of an Academic Medical Center. Participants were 50 euthyroid patients undergoing thyroidectomy. Thyroxine, triiodothyronine (T 3 ), and TSH levels were documented in patients prior to their scheduled thyroidectomy. Following thyroidectomy, patients were divided into those with a histologic diagnosis of either differentiated thyroid cancer or benign disease. Preoperative thyroid profiles were correlated with patients' postoperative diagnoses. Results: All patients had a normal serum TSH concentration preoperatively. One-third of the group was diagnosed with thyroid cancer as a result of their thyroidectomy. These patients had a higher serum TSH level (mean ¼ 1.50 mIU=L, CI 1.22-1.78 mIU=L) than patients with benign disease (mean ¼ 1.01 mIU=mL, CI 0.84-1.18 mIU=L). There was a greater risk of having thyroid cancer in patients with TSH levels in the upper three quartiles of TSH values, compared with patients with TSH concentrations in the lowest quartile of TSH values (odd ratio ¼ 8.7, CI 2.2-33.7). Patients with a thyroid cancer diagnosis also had lower T 3 concentrations measured by liquid chromatography tandem mass spectrometry (mean ¼ 112.6 ng=dL, CI 103.8-121.4 ng=dL) than did patients with a benign diagnosis (mean 129.9 ng=dL, CI 121.4-138.4 ng=dL). Conclusion: These data confirm that higher TSH concentrations, even within the normal range, are associated with a subsequent diagnosis of thyroid cancer in individuals with thyroid abnormalities. This further supports the hypothesis that TSH stimulates the growth or development of thyroid malignancy during its early or preclinical phase. We also show for the first time that patients with thyroid cancer also have lower T 3 levels than patients with benign disease.

show abstract

Human Thyroid Cancer: Membrane Thyrotropin Binding and Adenylate Cyclase Activity

Cited by 91 publications

References 12 publications

Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma

Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma

WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?

Endogenous Thyrotropin and Triiodothyronine Concentrations in Individuals with Thyroid Cancer

Contact Info

Product

Resources

About